Let’s start up with the current stock price of Protagonist Therapeutics Inc. (PTGX), which is $22.88 to be very precise. The Stock rose vividly during the last session to $25.41 after opening rate of $24.80 while the lowest price it went was recorded $23.87 before closing at $24.05.Recently in News on March 15, 2023, Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update. Positive results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235) in moderate-to-severe psoriasis, paving a path forward for initiation of a Phase 3 pivotal study. You can read further details here
Protagonist Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $27.41 on 03/18/22, with the lowest value was $6.91 for the same time period, recorded on 06/14/22.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Protagonist Therapeutics Inc. (PTGX) full year performance was -11.41%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Protagonist Therapeutics Inc. shares are logging -16.55% during the 52-week period from high price, and 231.04% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $6.91 and $27.41.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 709072 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Protagonist Therapeutics Inc. (PTGX) recorded performance in the market was 109.67%, having the revenues showcasing 158.18% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.15B, as it employees total of 122 workers.
Market experts do have their say about Protagonist Therapeutics Inc. (PTGX)
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 12.15, with a change in the price was noted +15.03. In a similar fashion, Protagonist Therapeutics Inc. posted a movement of +189.36% for the period of last 100 days, recording 1,286,630 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for PTGX is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Protagonist Therapeutics Inc. (PTGX)
Raw Stochastic average of Protagonist Therapeutics Inc. in the period of last 50 days is set at 81.93%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 74.58%. In the last 20 days, the company’s Stochastic %K was 85.13% and its Stochastic %D was recorded 91.36%.
Bearing in mind the latest performance of Protagonist Therapeutics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 109.67%. Additionally, trading for the stock in the period of the last six months notably improved by 177.95%, alongside a downfall of -11.41% for the period of the last 12 months. The shares increased approximately by -5.83% in the 7-day charts and went down by 44.60% in the period of the last 30 days. Common stock shares were driven by 158.18% during last recorded quarter.
